Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis

European Journal of Pharmacology

Volumn 692, Issue 1-3, 2012, Pages 19-28

  Zhang, Dong Mei ^a   Liu, Jun Shan ^a   Tang, Ming Kuen ^b   Yiu, Anita ^b   Cao, Hui Hui ^a   Jiang, Lei ^b   Yuet Wa Chan, Judy ^b   Tian, Hai Yan ^a   Fung, Kwok Pui ^b   Ye, Wen Cai ^a  

^a JINAN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Akt; Apoptosis; Bufotalin; Cell cycle arrest; Liver cancer; Multidrug resistant HepG2 cells

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AURORA A KINASE; BUFADIENOLIDE DERIVATIVE; BUFOTALIN; CASPASE 3; CASPASE 9; CHINESE DRUG; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VENENUM BUFONIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BUFO; BUFO BUFO GARGARIZANS; CALCIUM CELL LEVEL; CANCER CELL; CANCER INHIBITION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CANCER; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUFANOLIDES; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL CYCLE PROTEINS; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; M PHASE CELL CYCLE CHECKPOINTS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865838803     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.06.045     Document Type: Article

References (38)

1. T. Abbas, and A. Dutta p21 in cancer: intricate networks and multiple activities Nat. Rev. Cancer 9 2009 400 414
2. F.X. Bosch, J. Ribes, R. Cléries, and M. Díaz Epidemiology of hepatocellular carcinoma Clin. Liver Dis. 9 2005 191 211
3. R. Boutros, V. Lobjois, and B. Ducommun CDC25 phosphatases in cancer cells: key players? Good targets Nat. Rev. Cancer 7 2007 495 507
4. P.S. Brookes, Y. Yoon, J.L. Robotham, M.W. Ander, and S.S. Sheu Calcium, ATP, and ROS: a mitochondrial love-hate triangle Am. J. Physiol. Cell Physiol. 287 2004 817 833
5. J.Y. Chan, A.C. Chu, and K.P. Fung Inhibition of p-glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA Life Sci. 67 2000 2117 2124
6. J.Y. Chan, P.M. Tang, P.M. Hon, S.W. Au, S.K. Tsui, M.M. Waye, T.C. Mak, and K.P. Fung Pheophorbide a, a major antitumor component purified from Scutellaria barbata, induces apoptosis in human hepatocellular carcinoma cells Planta Med. 72 2006 28 33
7. J.P. Fruehauf, and F.L. Meyskens Reactive oxygen species: a break of life or death? Clin. Cancer Res. 13 2007 789 794
8. T.M. Gottlieb, J.F. Leal, R. Seger, Y. Taya, and M. Oren Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis Oncogene 21 2002 1299 1303
9. K.Q. Han, G. Huang, W. Gu, Y.H. Su, X.Q. Huang, and C.Q. Ling Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice World J. Gastroenterol. 13 2007 3374 3379
10. S. Hashimoto, Y. Jing, N. Kawazoe, Y. Masuda, S. Nakajo, T. Yoshida, Y. Kuroiwa, and K. Nakaya Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs Leuk. Res. 21 1997 875 883
11. X. He, J. Tang, A. Qiao, G. Wang, M. Jiang, R.H. Liu, and X. Yao Cytotoxic biotransformed products from cinobufagin by Mucor spinosus and Aspergillus Niger Steroids 71 2006 392 402
12. B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, and G.B. Mills Exploring the PI3K/AKT pathway for cancer drug discovery Nat. Rev. Drug Discov. 4 2005 988 1004
13. P. Kaldis, and E. Aleem Cell cycle sibling rivalry: Cdc2 versus Cdk2 Cell Cycle 4 2005 1491 1494
14. Y. Kamano, A. Kotake, H. Hashima, M. Inoue, H. Morita, K. Takeya, H. Itokawa, N. Nandachi, T. Segawa, A. Yukita, K. Saitou, M. Katsuyama, and G.R. Pettit Structure-cytotoxic activity relationship for the toad poison bufadienolides Bioorg. Med. Chem. 6 1998 1103 1105
15. Y. Kamano, A. Yamashita, T. Nogawa, H. Morita, K. Takeya, H. Itokawa, T. Segawa, A. Yukita, K. Saito, M. Katsuyama, and G.R. Pettit QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1) J. Med. Chem. 45 2002 5440 5447
16. J.K. Kim, and J.A. Diehl Nuclear cyclin D1: an oncogenic driver in human cancer J. Cell Physiol. 220 2009 292 296
17. C. Lexia, M. Bras, G. Fallot, N. Vadrot, F. Daniel, M. Lasfer, H. Tamouza, and A. Groyer Pleiotropic effects of PI-3 kinase/Akt signaling in human hepatoma cell proliferation and drug-induced apoptosis Ann. N.Y. Acad. Sci. 1090 2006 1 17
18. W.X. Li, H. Sun, Q. Li, X.Q. Zhang, W.C. Ye, and X.S. Yao Chemical components from skin of Bufo bufo gargarizans Cantor Chin. Trad. Herb. Drugs 38 2007 183 185
19. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
20. M. Malumbres, and M. Barbacid Cell cycle, CDKs and cancer: a changing paradigm Nat. Rev. Cancer 9 2009 153 166
21. M. Mandal, S. Kim, M.N. Younes, S.A. Jasser, A.K. El-Naggar, G.B. Mills, and J.N. Myers The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells Br. J. Cancer 92 2005 1899 1905
22. B.D. Manning, and L.C. Cantley AKT/PKB signaling: navigating downstream Cell 129 2007 1261 1274
23. L. Petraccia, P. Onori, R. Sferra, M.C. Lucchetta, G. Liberati, M. Grassi, and E. Gaudio MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications Clin. Ter. 154 2003 325 335
24. P. Pisani, D.M. Parkin, F. Bray, and J. Ferlay Estimates of the worldwide mortality from 25 cancers in 1990 Int. J. Cancer 83 1999 18 29
25. E.R. Plummer Inhibition of poly(ADP-ribose) polymerase in cancer Curr. Opin. Pharmacol. 6 2006 364 368
26. I. Prassas, and E.P. Diamandis Novel therapeutic applications of cardiac glycosides Nat. Rev. Drug Discov. 7 2008 926 935
27. J. Rudolph CDC25 phosphatases: structure, specificity and mechanism Biochemistry 46 2007 3595 3604
28. 2-induced neuroblastoma cell cytotoxicity by a triazine derivative, AA3E2 Eur. J. Pharmacol. 622 2009 1 6
29. W. Schoner, and G. Scheiner-Bobis Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth Am. J. Physiol. Cell Physiol. 293 2007 509 536
30. P.S. Steyn, and F.R. van Heerden Bufadienolides of plant and animal origin Nat. Prod. Rep. 15 1998 397 413
31. C.L. Su, T.Y. Lin, C.N. Lin, and S.J. Won Involvement of caspases and apoptosis-inducing factor in bufotalin-induced apoptosis of Hep3B cells J. Agric. Food Chem. 57 2009 55 61
32. P.M. Tang, J.Y. Chan, D.M. Zhang, S.W. Au, W.P. Fong, S.K. Kong, S.K. Tsui, M.M. Waye, T.C. Mak, and K.P. Fung Pheophorbide a, an active component in Scutellaria barbata, reverses p-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2 Cancer Biol. Ther. 6 2007 504 509
33. Z.Y. Tang Small hepatocellular carcinoma: current status and prospects Hepatobiliary Pancreat. Dis. Int. 1 2002 349 353
34. G. Vader, and S.M. Lens The Aurora kinase family in cell division and cancer Biochim. Biophys. Acta 1786 2008 60 72
35. L.H. Wang, and K.Z. Song Studies on the clinical application of Venenum Bufonis Chin. J. Mod. Appl. Pharm. 23 2006 618 620
36. T.H. Wang, H.S. Wang, and Y.K. Soong Paclitaxel-induced cell death: where the cell cycle and apoptosis come together Cancer 88 2000 2619 2628
37. M. Watabe, K. Ito, Y. Masuda, S. Nakajo, and K. Nakaya Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells Oncogene 16 1998 779 787
38. C.H. Yu, S.F. Kan, H.F. Pu, E. Jea Chien, and P.S. Wang Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells Cancer Sci. 99 2008 2467 2476